Traumatic Brain Injury
Therapeutics Market: Regional Analysis
On the basis of region, the
global Traumatic
Brain Injury Therapeutics Market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to
account for the largest market share in the traumatic brain injury therapeutics
market, owing to increasing incidences of TBI in the U.S. For instance,
according to CDC, in 2013, around 2.5 million patients with TBI visited the
emergency department and around 282,000 patients with TBI were hospitalized in
U.S. Moreover, according to the same source, around 56,000 deaths are
registered, annually due to TBI, accounting for 30% of all injury related
deaths in U.S.
Traumatic brain injury (TBI) is a
condition in which the brain is injured by external forces such as accidents,
sports injuries, and sometimes physical aggression. According to The Centers
for Disease Control and Prevention’s (CDC) definition, TBI is disruption in the
normal function of the brain that can be caused by a bump, blow, or jolt to the
head, or penetrating head injury. TBI can affect a person physically and
psychologically. Some of symptoms of TBI can be observed immediately after
injury and other can arise after some time interval. TBI can be classified as
mild and severe.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2496
Mild TBI can temporarily affect
the brain cells while severe TBI can result in bruising, torn tissues,
bleeding, and other physical damage to the brain. TBI shows several physical,
sensory, and cognitive or mental symptoms. Complications associated with TBI
include, altered consciousness, physical complication such as seizures,
headache, vertigo, and infections (Meningitis), intellectual problem,
communication problem, sensory problem, and degenerative brain diseases.
Treatments for TBI are based on the severity of the injury.
Traumatic Brain Injury
Therapeutics Market: Drivers
Increasing number of pipeline
studies to develop new treatments for TBI is expected to boost the traumatic
brain injury therapeutics market growth during the forecast period. For
instance, in August 2017, Australian and New Zealand Intensive Care Research
Center, in collaboration with Monash University, initiated a clinical trial to
determine long-term effects of erythropoietin in patients with moderate to
severe TBI. Erythropoietin is a hormone produced by the kidneys and plays
crucial role in the production of red blood cells (RBCs). The study is expected
to be completed by May 2019.
Similarly, in June 2016,
Vasopharm GmbH, in collaboration with ICON plc, started phase 3 clinical study
for VAS203 (Ronopterin) to evaluate its efficacy in patients with moderate and
severe TBI (NOSTRA-III). The study is expected to be completed by June 2019.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/traumatic-brain-injury-therapeutics-market-2496
However, delayed diagnosis of TBI
may hinder the traumatic brain injury therapeutics market growth. After brain
injury, brain undergoes hyper-metabolic state as it tries to protect itself
after injury. This hyper-metabolic activity mask the symptoms of brain injuries
which may result into delayed diagnosis of TBI.
Furthermore, Europe is expected
to account for the second largest market share in the traumatic brain injury
therapeutics market, owing to increasing government initiatives to develop new
treatment options for TBI. For instance, in 2017, ICON plc. announced its
contribution with pan-European traumatic brain injury (TBI) research study
involving over 4,500 patients in 65 sites in 20 European countries. ICON
provided site management and source data verification (SDV) services to the
study. The study was initiated with the support of European Union.
Key players operating in the
global traumatic brain injury therapeutics market include, Teva Pharmaceutical
Industries Ltd., Sanofi, Novartis AG, Pfizer Inc., Akorn Pharmaceuticals, Arbor
Pharmaceuticals, F. Hoffmann-La Roche Ltd., Invagen pharms, Lupin, Apotex Inc.,
Mylan N.V., Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc., and
Avanir Pharmaceuticals Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2496
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment